The Plasticity of CD4+CD25+FOXP3+CD127low T Cells in Patients with Metastatic Renal Cell Carcinoma in the Course of Interferon-Alpha Immunotherapy
| العنوان: | The Plasticity of CD4+CD25+FOXP3+CD127low T Cells in Patients with Metastatic Renal Cell Carcinoma in the Course of Interferon-Alpha Immunotherapy |
|---|---|
| المؤلفون: | Bykovskaia Sn, Maria S. Sayapina |
| المصدر: | Journal of Oncology, Vol 2018 (2018) |
| بيانات النشر: | Hindawi Limited, 2018. |
| سنة النشر: | 2018 |
| مصطلحات موضوعية: | 0301 basic medicine, Oncology, medicine.medical_specialty, education.field_of_study, Article Subject, business.industry, medicine.medical_treatment, Population, Alpha interferon, FOXP3, Immunotherapy, medicine.disease, lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens, lcsh:RC254-282, 03 medical and health sciences, 030104 developmental biology, Antigen, Renal cell carcinoma, Internal medicine, medicine, Progression-free survival, IL-2 receptor, business, education |
| الوصف: | Aims. To examine changes in subpopulation of CD4+CD25+Foxp3+CD127low T lymphocytes (Treg) and their association with the efficiency of the IFN-α therapy. Materials and Methods. Pts with mRCC who had undergone nephrectomy were treated with IFN-α at a dose of 6×106 U/day three times a week (n = 18). An immunophenotypic analysis of lymphocytes in peripheral blood expressing CD4, CD25, CD127, and Foxp3 antigens could be performed in 18 pts before, 2 weeks, and 2 mo after IFN-α therapy and 22 normal volunteers. Blood samples were collected at baseline and 2 mo after treatment start. Serum levels of TGF-β1, IL-17A, and Epo were measured by ELISA. Results. PR was achieved in 3 (16.6%) pts who received first-line therapy. Long-lasting SD (≥6 months) was noted in 6 (33.3%) pts. The median progression free survival (PFS) was 4 mo (95% CI: 2-NE). The study of the population of Treg indicated that there were no significant differences in the groups depending on the effect (p = 0.71). In one patient, the reduction of Treg cells was associated with increased TGF-β and IL-17 levels, whereas in other two pts the increase in Treg cells was associated with decreased TGF-β and IL-17 levels. The endogenous levels of Epo did not show significant correlation with response to IFN-α immunotherapy. In the patient subgroup with an initial value of MCH > 31 pg, the median PFS was not achieved, but in the subgroup with an initial value of MCH < 31 pg, the median PFS was 2 months (p = 0.032). Conclusions. In our study, we have described functional plasticity of Treg cells, which prevents them from being used as a prognostic marker. The conversion of Treg cells into Th17 can serve as a basis for the development of a new specific immunotherapeutic method in oncology after confirmation in the experiment in vitro. Given the small dataset, the results will need further validation. |
| وصف الملف: | text/xhtml |
| اللغة: | English |
| تدمد: | 1687-8469 1687-8450 |
| URL الوصول: | https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f3f386c6de8f53aae212efdb6925285a https://doaj.org/article/184e5c4697ad41b1b879042dd015e5ff |
| Rights: | OPEN |
| رقم الانضمام: | edsair.doi.dedup.....f3f386c6de8f53aae212efdb6925285a |
| قاعدة البيانات: | OpenAIRE |
| تدمد: | 16878469 16878450 |
|---|